Thank you, Joey, seriously. You nailed something that too often gets missed in the noise: regulatory infrastructure is as important as scientific innovation. Without a legal pathway, even the best therapy can be stalled or buried.
You’re right, Linda’s legal background has shaped every step of this. She’s been building protections before exposing the company to unnecessary risk. It’s why the MHRA route wasn’t just convenient, it was strategic. Specials gave patients a way in. SI 87 formalized the framework. And now, for the first time, we’re sitting at the edge of a fully legal, exportable, platform-based cell therapy system operating under UK law.
And this wasn’t just background lobbying. It’s on public record: Linda Powers was the sole representative from the oncology cell therapy sector to testify during the UK Parliament’s APPGBT inquiry in May 2022. Her recommendations were cited directly in the final report, and the MHRA reforms that followed, including SI 87, External Control Arm guidance, and the Real-World Evidence Joint Scientific Dialogue, align point for point with what she advocated.
She didn’t ask for special treatment. She laid out a regulatory blueprint, and now that blueprint is policy.
So your insight about offshore subsidization is spot on. This isn’t just about treating UK patients, it’s about enabling economic leverage. The UK gets jobs, GMP infrastructure, global licensing pull, and platform delivery. DCVax becomes not just a treatment, but the model that proves the NHS platform works.
So yes, it’s been a long wait. But I’d rather wait for a door that stays open than sprint through one that was never real.
We’re close. And more importantly, we’re ready.
Bullish
AI
Market Data 
Markets 
